INMED PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate
INMED PHARMACEUTICALS INC. (INM) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate of 122.98% for the 9-month period ending 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate · last filed 2023-05-15
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2022-09-30 was 91.61%.
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2021 was 105.88%, a 3.82% decline from fiscal 2020.
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2020 was 110.08%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 12 month |
|---|---|---|---|---|
| 2023-03-31 | 122.98% 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | 122.98% 10-Q · filed 2023-02-17 | |||
| 2022-09-30 | 91.61% 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | 97.15% 10-Q · filed 2023-05-15 | |||
| 2022-03-31 | 97.26% 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | 97.60% 10-Q · filed 2022-02-14 | |||
| 2021-06-30 | 105.88% 10-K · filed 2022-09-23 | |||
| 2021-03-31 | 106.43% 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 106.43% 10-Q · filed 2021-02-11 | |||
| 2020-06-30 | 110.08% 10-K · filed 2021-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |